BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 33985974)

  • 1. Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer.
    Shan P; Yang F; Qi H; Hu Y; Zhu S; Sun Z; Zhang Z; Wang C; Hou C; Yu J; Wang L; Zhou Z; Li P; Zhang H; Wang K
    Cancer Res; 2021 Aug; 81(15):4027-4040. PubMed ID: 33985974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
    Gao C; Xiao G; Piersigilli A; Gou J; Ogunwobi O; Bargonetti J
    Breast Cancer Res; 2019 Jan; 21(1):5. PubMed ID: 30642351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells.
    Lei M; Zhang YL; Huang FY; Chen HY; Chen MH; Wu RH; Dai SZ; He GS; Tan GH; Zheng WP
    Sci Rep; 2023 Dec; 13(1):21916. PubMed ID: 38081931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting G-rich sequence to regulate the transcription of murine double minute (MDM) genes in triple-negative breast cancers.
    Feng Y; Xuan X; Hu Y; Lu J; Dong Z; Sun Z; Yao H; Hu L; Yin Q; Liu Y; Wang H
    Eur J Med Chem; 2024 Mar; 267():116156. PubMed ID: 38295687
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative Breast Cancer.
    Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
    Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.
    Su Y; Hopfinger NR; Nguyen TD; Pogash TJ; Santucci-Pereira J; Russo J
    J Exp Clin Cancer Res; 2018 Dec; 37(1):314. PubMed ID: 30547810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potentiation of Carboplatin-Mediated DNA Damage by the Mdm2 Modulator Nutlin-3a in a Humanized Orthotopic Breast-to-Lung Metastatic Model.
    Tonsing-Carter E; Bailey BJ; Saadatzadeh MR; Ding J; Wang H; Sinn AL; Peterman KM; Spragins TK; Silver JM; Sprouse AA; Georgiadis TM; Gunter TZ; Long EC; Minto RE; Marchal CC; Batuello CN; Safa AR; Hanenberg H; Territo PR; Sandusky GE; Mayo LD; Eischen CM; Shannon HE; Pollok KE
    Mol Cancer Ther; 2015 Dec; 14(12):2850-63. PubMed ID: 26494859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
    Li M; Li A; Zhou S; Lv H; Yang W
    J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
    Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
    Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
    Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
    Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
    [No Abstract]   [Full Text] [Related]  

  • 13. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
    Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
    Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
    Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mdm2 and MdmX partner to regulate p53.
    Wang X; Jiang X
    FEBS Lett; 2012 May; 586(10):1390-6. PubMed ID: 22673503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actin-like protein 6A/MYC/CDK2 axis confers high proliferative activity in triple-negative breast cancer.
    Jian Y; Huang X; Fang L; Wang M; Liu Q; Xu H; Kong L; Chen X; Ouyang Y; Wang X; Wei W; Song L
    J Exp Clin Cancer Res; 2021 Feb; 40(1):56. PubMed ID: 33541412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
    Wang X
    Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 E3 ligase-mediated ubiquitination and degradation of HDAC1 in vascular calcification.
    Kwon DH; Eom GH; Ko JH; Shin S; Joung H; Choe N; Nam YS; Min HK; Kook T; Yoon S; Kang W; Kim YS; Kim HS; Choi H; Koh JT; Kim N; Ahn Y; Cho HJ; Lee IK; Park DH; Suk K; Seo SB; Wissing ER; Mendrysa SM; Nam KI; Kook H
    Nat Commun; 2016 Feb; 7():10492. PubMed ID: 26832969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX inhibitory protein in wild-type p53 breast cancer cells.
    Geng QQ; Dong DF; Chen NZ; Wu YY; Li EX; Wang J; Wang SM
    Int J Oncol; 2013 Dec; 43(6):1935-42. PubMed ID: 24126697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.